<DOC>
	<DOCNO>NCT00350051</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment new drug call ZK-Epothilone ( ZK-Epo ) give prednisone patient androgen-independent prostate cancer , previous chemotherapy , safe help decrease PSA ( Prostate-specific antigen ) level .</brief_summary>
	<brief_title>ZK-Epo Given With Prednisone Patients With Metastatic Androgen-independent Prostate Cancer</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Schering AG , Germany.Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. , Schering AG Germany rename Bayer Schering Pharma AG , Germany . Bayer HealthCare Pharmaceuticals , Inc.and Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Must evidence confirm metastatic prostate cancer Serum testosterone must less 50 ng/mL Disease must progress despite antiandrogen therapy PSA level must elevate Additional criterion determine screen visit Any previous cytotoxic chemotherapy prostate cancer Use investigational drug last 4 week Symptomatic brain tumor require radiation brain Active infection Additional criterion determine screen visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Metastatic androgen-independent prostate cancer</keyword>
</DOC>